2004 Annual Meeting | Non-Alzheimer's Dementia

Date Monday 04/26/04

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Jeffrey L. Cummings, MD, FAAN

Topic(s) Aging/Dementia/Degenerative Disease

Learning Objectives Upon completion:
Participants should know the principal clinical features of frontotemporal lobar degeneration, dementia with Lewy bodies, and vascular dementia that distinguish them from Alzheimer's disease; know the principal treatments that are available for non-AD dementias; and understand evolving concepts of protein metabolism disturbances underlying degenerative dementias.

CME Available No CME available

Program Level Introductory

Recommended Audience Practitioner, Fellow, Resident

Event Timeline
09:00 AM - 09:45 AM		Dementia with Lewy Bodies Daniel Kaufer, MD, FAAN
09:45 AM - 10:30 AM		Picks Disease and the Frontotemporal Dementias: Clinical and Biological Overview Bruce L. Miller, MD, FAAN
10:30 AM - 10:45 AM		Break
10:45 AM - 11:30 AM		Vascular Cognitive Impairment Charles S. DeCarli, MD, FAAN
11:30 AM - 12:15 PM		Phenotype-Prototype Relationships in Neurodegenerative Dementias Jeffrey L. Cummings, MD, FAAN
12:15 PM - 12:45 PM		Questions and Answers

Faculty Disclosures
Jeffrey L. Cummings, MD, FAAN	Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
Bruce L. Miller, MD, FAAN	Dr. Miller has nothing to disclose.
Charles S. DeCarli, MD, FAAN	Dr. DeCarli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. DeCarli has received research support from NIH.
Daniel Kaufer, MD, FAAN	No disclosure on file

��ɫ��

��ɫ��